April 1st 2025
Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.
Type 2 Diabetes, Metformin, and Cardioprotection: Are the Data There?
May 14th 2013Metformin and the class of sulfonylureas are the "work horses" of therapy for type 2 diabetes. Metformin even confers some protection from vascular complications. But, how do they stack up against newer agents? Here, a closer look.